Case Reports

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab, Gregg A. Staerkel, Priyadharsini Nagarajan, Carlos A. Torres-Cabala, Beth A. Chasen, Jennifer A. Wargo, Victor G. Prieto, Rodabe N. Amaria, Jonathan L. Curry

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 14; DOI: 10.1186/s40425-018-0323-0
Ipilimumab induced digital vasculitis
Amrita Padda, Elena Schiopu, Justin Sovich, Vincent Ma, Ajjai Alva, Leslie Fecher

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 12; DOI: 10.1186/s40425-018-0321-2
Progressive hypoventilation due to mixed CD8⁺ and CD4⁺ lymphocytic polymyositis following tremelimumab - durvalumab treatment
Sooraj John, Scott J. Antonia, Trevor A. Rose, Robert P. Seifert, Barbara A. Centeno, Aaron S. Wagner, Ben C. Creelan

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 54; DOI: 10.1186/s40425-017-0258-x
Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes
Michael C. Topf, Madalina Tuluc, Larry A. Harshyne, Adam Luginbuhl

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 60; DOI: 10.1186/s40425-017-0264-z
Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
Raphael B. Moreira, Lana Hamieh, Evisa Gjini, Ana Lako, Katherine M. Krajewski, Charles H. Yoon, Patrick A. Ott

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 61; DOI: 10.1186/s40425-017-0259-9
Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma
Lea Bottlaender, Anne-Laure Breton, Louis de Laforcade, Frederique Dijoud, Luc Thomas, Stephane Dalle

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 57; DOI: 10.1186/s40425-017-0261-2
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report
Simran Sindhu, Lana H. Gimber, Lee Cranmer, Ali McBride, Andrew S. Kraft

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 58; DOI: 10.1186/s40425-017-0263-0
Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition
Quaovi Sodji, Kandy Klein, Kavuri Sravan, Jigarkumar Parikh

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 62; DOI: 10.1186/s40425-017-0267-9
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
Dylan J. Martini, Aly-Khan A. Lalani, Dominick Bossé, John A. Steinharter, Lauren C. Harshman, F. Stephen Hodi, Patrick A. Ott, Toni K. Choueiri

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 66; DOI: 10.1186/s40425-017-0273-y
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal, David Jablons

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 75; DOI: 10.1186/s40425-017-0281-y

Main menu

Case Reports

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Case Reports

Pages